I. Cicin Et Al. , "Characteristics of Turkish colorectal cancer patients and bevacizumab preference.," 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , vol.35, Illinois, United States Of America, 2017
Cicin, I. Et Al. 2017. Characteristics of Turkish colorectal cancer patients and bevacizumab preference.. 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , (Illinois, United States Of America).
Cicin, I., Gumus, M., Uncu, D., Ozkan, M., Kilickap, S., Elkiran, T. E., ... Isikdogan, A.(2017). Characteristics of Turkish colorectal cancer patients and bevacizumab preference. . 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America
Cicin, Irfan Et Al. "Characteristics of Turkish colorectal cancer patients and bevacizumab preference.," 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2017
Cicin, Irfan Et Al. "Characteristics of Turkish colorectal cancer patients and bevacizumab preference.." 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , Illinois, United States Of America, 2017
Cicin, I. Et Al. (2017) . "Characteristics of Turkish colorectal cancer patients and bevacizumab preference.." 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Irfan Cicin Et Al. }, title={Characteristics of Turkish colorectal cancer patients and bevacizumab preference.}, congress name={53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET}, city={Illinois}, country={United States Of America}, year={2017}}